Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 not yet has established its treatment, but convalescent plasma has been expected to increase survival rates as in the case with other emerging viral infections. We describe two cases of COVID-19 treated with convalescent plasma infusion. Both patients presented severe pneumonia with acute respiratory distress syndrome and showed a favorable outcome after the use of convalescent plasma in addition to systemic corticosteroid. To our knowledge, this is the first report of the use of convalescent plasma therapy for COVID-19 in Korea.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152526 | PMC |
| http://dx.doi.org/10.3346/jkms.2020.35.e149 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pediatric and Adult Inborn Errors of Immunity and COVID-19: A Comparative Study.
J Med Virol
September 2025
Department of Pediatrics, Division of Immunology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
COVID-19 has worse clinical outcomes in inborn errors of immunity (IEI) patients. We aimed to determine COVID-19-related hospitalization/ICU admission/mortality risk in patients with IEI. We included 62 COVID-19 (29 children and 33 adults) in a referral center.
View Article and Find Full Text PDFSARS-CoV-2 antibody responses in children exhibit higher FcR engagement and avidity than in adults.
Nat Commun
August 2025
HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
As intrinsic differences in humoral immune response to SARS-CoV-2 between children and adults remain unclear, we improved characterisation by defining the kinetics, specificity and function of antibodies to SARS-CoV-2 in children (n = 146, aged 9.4 ± 4.8 years with n = 257 samples) compared to adults (n = 85, aged 39.
View Article and Find Full Text PDFHigh-dimensional single-cell phenotyping unveils persistent differences in immune cell profiles between severe and moderate seasonal influenza.
Front Immunol
August 2025
Section of Immunology, Department of Method Development and Analytics, Norwegian Institute of Public Health, Oslo, Norway.
Background: Influenza viruses with pandemic potential and possible burden of post-viral sequelae are a global concern. To prepare for future pandemics and the development of improved vaccines, it is vital to identify the immunological changes underlying influenza disease severity.
Methods: We combined unsupervised high-dimensional single-cell mass cytometry with gene expression analyses, plasma CXCL13 measurements, and antigen-specific immune cell assays to characterize the immune profiles of hospitalized patients with severe and moderate seasonal influenza disease during active infection and at 6-month follow-up.
Author's Reply to the correspondence: ECIL-10 guidelines for COVID-19 should take convalescent plasma into proper consideration by Focosi et al.
Leukemia
September 2025
Department of Haematology, Hospital de la Princesa, Madrid, Spain.
Development of in vitro plaque-based assay for assessment of antibody-dependent enhancement in SARS-CoV-2 infection.
J Immunol Methods
September 2025
Thailand-Japan Research Collaboration Center on Emerging and Re-emerging Infections (RCC-ERI), Department of Medical Sciences, Ministry of Public Health, Nonthaburi 11000, Thailand; Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan. Electronic address:
Antibody-dependent enhancement (ADE) of infection is a concerning phenomenon in SARS-CoV-2 infection, since it may develop disease severity. Although ADE has been demonstrated in animal models, the pathogenic mechanism has not been fully elucidated. The present study aimed to develop a simple assay system for detecting SARS-CoV-2 ADE activity in any antibody specimen.
View Article and Find Full Text PDF